COMBINED VBM (VINBLASTINE, BLEOMYCIN, METHOTREXATE) CHEMOTHERAPY AND INVOLVED FIELD (IF) RADIOTHERAPY (RT) IN EARLY STAGE HODGKIN'S LYMPHOMA (HL): A SINGLE CENTRE EXPERIENCE

被引：0
|
作者：
Cocorocchio, E. [1 ]
Bassi, S. [1 ]
Negri, M. [1 ]
Peccatori, F. A. [1 ]
Travaini, L. L. [1 ]
Piperno, G. [1 ]
Preda, L. [1 ]
Pruneri, G. [1 ]
Vanazzi, A. [1 ]
Alietti, A. [1 ]
Martinelli, G. [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1641
引用
收藏
页码：631 / 632
页数：2
相关论文
共 50 条
  • [31] COMBINED ABVD AND INVOLVED FIELD LOW DOSE RADIOTHERAPY FOR ADVANCED CHILDHOOD HODGKIN LYMPHOMA: SINGLE INSTITUTION RESULTS
    Zubizarreta, Pedro
    Vides Herrera, Maria Soledad
    Galluzzo, Laura
    Raslawski, Elsa
    Braier, Jorge
    Rose, Adriana
    Chantada, Guillermo
    Cacciavillano, Walter
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 784 - 784
  • [32] Fifteen year experience of A(E)BVD chemotherapy plus low dose involved field radiation therapy for early clinical stage Hodgkin's lymphoma (HL). Does radiation dose affect patients' outcome?
    Vassilakopoulos, TP
    Angelopoulou, MK
    Siakantaris, MP
    Kyrtsonis, MC
    Kontopidou, FN
    Dimopoulou, MN
    Kokoris, SI
    Dimitriadou, E
    Tsaftaridis, P
    Variamis, E
    Zambatis, H
    Michalopoulos, E
    Boussiotis, VA
    Panagiotidis, P
    Papavassileiou, K
    Pangalis, GA
    BLOOD, 2003, 102 (11) : 405A - 405A
  • [33] Improved outcome in British Columbia with optimized combined modality treatment for early stage Hodgkin's lymphoma (HL).
    Connors, JM
    Fairey, R
    Gascoyne, RD
    Hoskins, P
    Kasa, RJ
    Sehn, L
    Shenkier, TN
    Voss, NJ
    O'Reilly, SE
    BLOOD, 2000, 96 (11) : 134A - 134A
  • [34] Non-Hodgkin's lymphoma of Waldeyer's ring in children: Outcome using chemotherapy and involved field radiotherapy
    Laskar, S.
    Bahl, G.
    Muckaden, M. A.
    Pai, S.
    Nair, R.
    Gupta, S.
    Shet, T.
    Gujral, S.
    Arora, B.
    Sengar, M.
    Shrivastava, S. K.
    Dinshaw, K. A.
    CLINICAL ONCOLOGY, 2008, 20 (08) : 613 - 618
  • [35] CHEMOTHERAPY OR CHEMOTHERAPY PLUS RADIOTHERAPY IN EARLY HODGKIN'S LYMPHOMA ? FINAL RESULTS OF A RETROSPECTIVE ANALYSIS OF A REGIONAL ITALIAN EXPERIENCE
    Clavio, M.
    Olcese, F.
    Rossi, E.
    Spriano, M.
    Ballerini, F.
    Canepa, L.
    Pierri, I.
    aquino, S.
    Varaldo, R.
    Cavaliere, M.
    Manna, A.
    Secondo, V.
    Racchi, O.
    Balleari, E.
    Napoli, S.
    Carella, A. M.
    Ghio, R.
    Gobbi, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 247 - 247
  • [36] Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy
    Gobbi, Paolo G.
    Bergonzi, Manuela
    Bassi, Emilio
    Merli, Francesco
    Coriani, Chiara
    Federico, Massimo
    HEMATOLOGICAL ONCOLOGY, 2013, 31 (03) : 151 - 155
  • [37] Bortezomib (velcade) combined to involved field radiotherapy(IFR) in refractory/relapse Hodgkin Lymphoma(HL) as salvage therapy: Report of two cases
    Fenu, S.
    Bongarzoni, V
    Chierichini, A.
    Anaclerico, B.
    Anticoli-Borza, P.
    Ronci, B.
    Cedrone, M.
    Bartolini, M.
    Iacovino, P.
    Monardo, F.
    Ferretti, G.
    Caspiani, O.
    Annino, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 188 - 188
  • [38] Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial
    Borchmann, Peter
    Diehl, Volker
    Goergen, Helen
    Mueller, Horst
    Mueller, Rolf Peter
    Eich, Hans T.
    Mueller-Hermelink, Hans Konrad
    Herrmann, Richard
    Markova, Jana
    Ho, Anthony D.
    Hiddemann, Wolfgang
    Doerken, Bernd
    Greil, Richard
    Engert, Andreas
    BLOOD, 2009, 114 (22) : 299 - 300
  • [39] Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin Lymphoma (HL): Final analysis of the German Hodgkin Study Group (GHSG) HD11 trial
    Borchmann, P.
    Diehl, V
    Goergen, H.
    Mueller, H.
    Mueller, R. P.
    Eich, H.
    Mueller-Hermelink, K.
    Herrmann, R.
    Markova, J.
    Ho, A.
    Hiddemann, W.
    Doerken, B.
    Greil, R.
    Engert, A.
    ONKOLOGIE, 2010, 33 : 125 - 125
  • [40] COMBINED MODALITY TREATMENT WITH INTENSIFIED CHEMOTHERAPY AND DOSE-REDUCED INVOLVED FIELD RADIOTHERAPY IN PATIENTS WITH EARLY UNFAVOURABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD11 TRIAL
    Engert, A.
    Borchmann, P.
    Diehl, V.
    Goergen, H.
    Mueller, H.
    Mueller, R.
    Eich, H.
    Mueller-Hermelink, H.
    Herrmann, R.
    Markova, J.
    Ho, A.
    Hiddemann, W.
    Doerken, B.
    Greil, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 167 - 167
12345